HIV

Bio-Rad Laboratories has secured approval from the US Food and Drug Administration (FDA) for its Bio-Rad BioPlex 2200 HIV Ag-Ab assay.

The assay is designed to differentiate between HIV-1 antibodies, HIV-2 antibodies, and HIV-1 p24 antigen in human serum or plasma specimens.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Specifically, the test assists in the diagnosis of infection with HIV-1 and / or HIV-2, including acute HIV-1 infection in adults, children two years of age and older, as well as in pregnant women.

FDA Center for Biologics Evaluation and Research director Karen Midthun said: "Today’s approval provides healthcare professionals another option for the diagnosis of HIV infections.

"The ability to diagnose HIV infection early and differentiate between types of infection is important in the care of individuals, as both diseases exhibit the same symptoms but progress at different rates."

"The ability to diagnose HIV infection early and differentiate between types of infection is important in the care of individuals."

The BioPlex 2200 HIV Ag-Ab assay allows results of antigen and antibody detection to be reported separately, enabling differentiation between acute and established HIV infection respectively.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Intended for use with the BioPlex 2200 System, which was cleared by the FDA in 2004, the assay can also be used to screen organ donors for HIV-1/2 when the blood specimen is collected, while the donor’s heart is still beating.

However, the assay is not approved for use in screening blood or plasma donors, except in urgent situations where legacy licensed blood donor screening tests are unavailable or their use is impractical.

Both the HIV-1 and HIV-2 are similar, but distinct viruses.

The HIV-1 is responsible for majority of HIV infections worldwide, while HIV-2 is found primarily in West Africa, with some cases of the HIV-2 infection also being identified in the US.


Image: A scanning electron micrograph of HIV-1 budding from cultured lymphocyte. Photo: courtesy of C. Goldsmith.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact